Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

被引:18
|
作者
Chien, A. Jo [1 ]
Rugo, Hope S. [1 ]
机构
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
关键词
Metastatic breast cancer; Brain metastases; HER2; NERVOUS-SYSTEM METASTASES; LAPATINIB PLUS CAPECITABINE; TYROSINE KINASE INHIBITOR; AFATINIB BIBW 2992; CELL LUNG-CANCER; PHASE-II TRIAL; LEPTOMENINGEAL METASTASES; MENINGEAL CARCINOMATOSIS; INTRATHECAL TRASTUZUMAB; CNS METASTASES;
D O I
10.1007/s10549-012-2328-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The widespread use of trastuzumab in the past decade has led to a significant and measureable improvement in the survival of patients with human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer, and in many ways has redefined the natural history of this aggressive breast cancer subtype. Historically, survival in patients with HER2-positive disease was dictated by the systemic disease course, and what appears to be the central nervous system (CNS) tropism associated with HER2-amplified tumors was not clinically evident. With improved systemic control and prolonged survival, the incidence of brain metastases has increased, and CNS disease, often in the setting of well-controlled extracranial disease, is proving to be an increasingly important and clinically challenging cause of morbidity and mortality in patients with HER2-positive advanced breast cancer. This review summarizes the known clinical data for the systemic treatment of HER2-positive CNS metastases and includes information about ongoing clinical trials of novel therapies as well as emerging strategies for early detection and prevention.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [21] Optimizing the Management of Metastatic HER2-Positive Breast Cancer
    Goel S.
    Tolaney S.
    Current Breast Cancer Reports, 2015, 7 (4) : 190 - 202
  • [22] Tucatinib in the Treatment of HER2-positive Breast Cancer High Activity even in Patients with Brain Metastases
    Banys-Paluchowski, Maggie
    Krawczyk, Natalia
    ONKOLOGE, 2020, 26 (10): : 966 - 969
  • [23] GOOD RESULTS OF INTENSIVE SYSTEMIC TREATMENT OF PATIENTS WITH HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES
    Niwinska, Anna
    Murawska, Magdalema
    BREAST, 2013, 22 : S40 - S40
  • [24] Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
    Garcia-Alvarez, Alejandro
    Papakonstantinou, Andri
    Oliveira, Mafalda
    CANCERS, 2021, 13 (12)
  • [25] Treatment of HER2-Positive Metastatic Breast Cancer REPLY
    Swain, Sandra M.
    Clark, Emma
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1965
  • [26] Updates in Treatment of HER2-positive Metastatic Breast Cancer
    Avelino, Alzira R. M.
    Pulipati, Soumya
    Jamouss, Kevin
    Bhardwaj, Prarthna V.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (12) : 1471 - 1481
  • [27] The changing treatment of metastatic her2-positive breast cancer
    Mitsogianni, Maria
    Trontzas, Ioannis P.
    Gomatou, Georgia
    Ioannou, Stephanie
    Syrigos, Nikolaos K.
    Kotteas, Elias A.
    ONCOLOGY LETTERS, 2021, 21 (04)
  • [28] Optimizing treatment of HER2-positive metastatic breast cancer
    Jones, AL
    Leyland-Jones, B
    SEMINARS IN ONCOLOGY, 2004, 31 (05) : 29 - 34
  • [29] Margetuximab for the treatment of HER2-positive metastatic breast cancer
    Tarantino, Paolo
    Morganti, Stefania
    Uliano, Jacopo
    Giugliano, Federica
    Crimini, Edoardo
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
  • [30] Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
    Maurer, Christian
    Tulpin, Lorraine
    Moreau, Michel
    Dumitrescu, Cristina
    de Azambuja, Evandro
    Paesmans, Marianne
    Nogaret, Jean-Marie
    Piccart, Martine J.
    Awada, Ahmad
    ESMO OPEN, 2018, 3 (06)